IDX 1197

Drug Profile

IDX 1197

Alternative Names: IDX 1197 HCl; IDX-1197; NOV 1401 - National OncoVenture; NOV 140101

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ildong Pharmaceutical
  • Developer Ildong Pharmaceutical; National OncoVenture
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Oct 2017 Preclinical data in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 29 Aug 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in South Korea (PO) (NCT03317743)
  • 01 Aug 2017 Preclinical trials in Solid tumours in South Korea (PO) before August 2017 (National OncoVenture pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top